The 6 key players our Diabetes Drugs report profiles.
In the order our report profiles them, not ranked by sales. Each name opens the company's page with its public records.
| # | Company | Website | Our reports |
|---|---|---|---|
| 1 | Novo Nordisk A/S |
novo.com (opens in a new tab) | 545 reports |
| 2 | Eli Lilly and Company |
lilly.com (opens in a new tab) | 1,106 reports |
| 3 | Sanofi |
sanofi.com (opens in a new tab) | 1,436 reports |
| 4 | AstraZeneca |
astrazeneca.com (opens in a new tab) | 1,007 reports |
| 5 | Merck & Co., Inc. |
merck.com (opens in a new tab) | 1,470 reports |
| 6 | Boehringer Ingelheim GmbH |
boehringer-ingelheim.com (opens in a new tab) | 397 reports |
One report for each place. Each tile opens that place's report.
Compare all 50 places for Diabetes Drugs, with active trials
Company profiles, market shares and strategies come with the full report, with researched size, forecast, growth and segments.
Key players are our report's research. Other companies and trial counts come from free public records, each with its source. Acuitas market figures are not published on this page.